AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
Taking everything into account, AMED scores 5 out of 10 in our fundamental rating. AMED was compared to 102 industry peers in the Health Care Providers & Services industry. While AMED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMED has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AMED was profitable.
AMED had a positive operating cash flow in the past year.
Of the past 5 years AMED 4 years were profitable.
In the past 5 years AMED always reported a positive cash flow from operatings.
1.2 Ratios
AMED's Return On Assets of 4.11% is fine compared to the rest of the industry. AMED outperforms 73.53% of its industry peers.
AMED has a Return On Equity of 7.49%. This is in the better half of the industry: AMED outperforms 67.65% of its industry peers.
With an excellent Return On Invested Capital value of 10.15%, AMED belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMED is in line with the industry average of 9.53%.
The last Return On Invested Capital (10.15%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROIC | 10.15% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
Looking at the Profit Margin, with a value of 3.79%, AMED is in the better half of the industry, outperforming 71.57% of the companies in the same industry.
In the last couple of years the Profit Margin of AMED has declined.
AMED's Operating Margin of 9.17% is amongst the best of the industry. AMED outperforms 80.39% of its industry peers.
AMED's Operating Margin has been stable in the last couple of years.
The Gross Margin of AMED (43.37%) is better than 72.55% of its industry peers.
In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
AMED has more shares outstanding than it did 1 year ago.
AMED has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMED has been reduced compared to a year ago.
2.2 Solvency
AMED has an Altman-Z score of 3.93. This indicates that AMED is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.93, AMED is doing good in the industry, outperforming 75.49% of the companies in the same industry.
AMED has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
The Debt to FCF ratio of AMED (1.69) is better than 85.29% of its industry peers.
AMED has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
AMED has a Debt to Equity ratio of 0.28. This is in the better half of the industry: AMED outperforms 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 3.93 |
ROIC/WACC1.16
WACC8.77%
2.3 Liquidity
A Current Ratio of 1.29 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a worse Current ratio (1.29) than 61.76% of its industry peers.
A Quick Ratio of 1.29 indicates that AMED should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.29, AMED perfoms like the industry average, outperforming 44.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.86% over the past year.
AMED shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.46% yearly.
Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 5.34% in the last year.
AMED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.73% yearly.
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
3.2 Future
The Earnings Per Share is expected to grow by 7.37% on average over the next years.
AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.80% yearly.
EPS Next Y12.77%
EPS Next 2Y11.59%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue Next Year4.67%
Revenue Next 2Y5.25%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.91 indicates a rather expensive valuation of AMED.
66.67% of the companies in the same industry are more expensive than AMED, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.60, AMED is valued a bit cheaper.
The Price/Forward Earnings ratio is 17.65, which indicates a rather expensive current valuation of AMED.
AMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 65.69% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMED to the average of the S&P500 Index (22.43), we can say AMED is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.91 | ||
| Fwd PE | 17.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than 64.71% of the companies in the same industry.
79.41% of the companies in the same industry are more expensive than AMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.22 | ||
| EV/EBITDA | 11.47 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y11.59%
EPS Next 3Y7.37%
5. Dividend
5.1 Amount
AMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
94.74
+0.62 (+0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.9%
Inst Owner Change-1.51%
Ins Owners1.76%
Ins Owner Change5.17%
Market Cap3.11B
Analysts53.75
Price Target102.85 (8.56%)
Short Float %7.71%
Short Ratio6.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-10.15%
Max EPS beat(2)12.12%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-15.99%
Max EPS beat(4)12.12%
EPS beat(8)3
Avg EPS beat(8)-0.55%
EPS beat(12)6
Avg EPS beat(12)2.46%
EPS beat(16)8
Avg EPS beat(16)2.78%
Revenue beat(2)0
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-2.05%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-1.99%
Revenue beat(12)1
Avg Revenue beat(12)-2.69%
Revenue beat(16)1
Avg Revenue beat(16)-2.79%
PT rev (1m)3.95%
PT rev (3m)3.55%
EPS NQ rev (1m)-1.71%
EPS NQ rev (3m)-5.85%
EPS NY rev (1m)1.47%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-1.14%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)-0.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.91 | ||
| Fwd PE | 17.65 | ||
| P/S | 1.31 | ||
| P/FCF | 14.22 | ||
| P/OCF | 13.85 | ||
| P/B | 2.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.47 |
EPS(TTM)4.53
EY4.78%
EPS(NY)5.37
Fwd EY5.66%
FCF(TTM)6.66
FCFY7.03%
OCF(TTM)6.84
OCFY7.22%
SpS72.26
BVpS36.55
TBVpS-2.88
PEG (NY)1.64
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROCE | 12.85% | ||
| ROIC | 10.15% | ||
| ROICexc | 12.2% | ||
| ROICexgc | 151.22% | ||
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% | ||
| FCFM | 9.22% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 9.64% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 7.77 | ||
| Cash Conversion | 80.59% | ||
| Profit Quality | 243.34% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.93 |
F-Score7
WACC8.77%
ROIC/WACC1.16
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.86%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%21.36%
EPS Next Y12.77%
EPS Next 2Y11.59%
EPS Next 3Y7.37%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%4.09%
Revenue Next Year4.67%
Revenue Next 2Y5.25%
Revenue Next 3Y4.8%
Revenue Next 5YN/A
EBIT growth 1Y18.92%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year17.41%
EBIT Next 3Y9.44%
EBIT Next 5YN/A
FCF growth 1Y112.26%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y102.82%
OCF growth 3Y5.48%
OCF growth 5Y1.88%